MyOme has announced the launch of its coronary artery disease (CAD) polygenic risk modelling (PRS) product—Integrated PRS, CAD—CAD iPRS.
CAD iPRS integrates whole-genome sequencing data with clinical risk factors to provide a more accurate risk assessment for CAD compared to using traditional clinical factors alone, the company says in a press release. CAD iPRS is validated across multiple ancestries and provides a ten-year absolute risk of developing CAD.
The launch of CAD iPRS is supported by a validation study presented at the American College of Medical Genetics (ASHG) annual meeting (5–9 November, Denver, USA), demonstrating that integrating a cross-ancestry polygenic risk score with traditional clinical factors significantly improves 10-year absolute risk prediction for CAD.
The study validated the caPRS across multiple cohorts, including UK Biobank, MESA, Penn Medicine BioBank, and ARIC, showing its effectiveness across diverse ancestries. By combining genetics with the commonly used ASCVD Pooled Cohort Equation (PCE) into an integrated risk score (caIRS), the model improved risk discrimination and identified up to 27 additional CAD cases per 1,000 individuals in the borderline/intermediate PCE group. This enhanced stratification provides clinicians with a more precise tool to guide treatment decisions, particularly for patients with uncertain clinical risk.
“The launch of CAD iPRS supports our mission of leveraging the power of the genome to improve health outcomes for those at risk for the most deadly diseases,” said Premal Shah, CEO of MyOme. “Physicians can now more accurately assess risk across their diverse patient population and develop a screening and treatment plan for even those cases that were traditionally challenging. In doing so, physicians can potentially help their patients eliminate or delay the onset of CAD.”
